STPRD

Significance of TDP-43 in the population in relation to dementia

Coordinatore	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE    more  Organization address address: The Old Schools, Trinity Lane city: CAMBRIDGE postcode: CB2 1TN contact info Titolo: Prof. Nome: Carol Cognome: Brayne Email: send email Telefono: +44 (0) 1223 330334 Fax: +44 (0) 1223 330330
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	182˙484 €
EC contributo	182˙484 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IIF-2008
Funding Scheme	MC-IIF
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-04-04   -   2011-09-03

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE  Organization address address: The Old Schools, Trinity Lane city: CAMBRIDGE postcode: CB2 1TN contact info Titolo: Prof. Nome: Carol Cognome: Brayne Email: send email Telefono: +44 (0) 1223 330334 Fax: +44 (0) 1223 330330	UK (CAMBRIDGE)	coordinator	182˙484.78

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The incidence and prevalence of dementia is rising as the world-wide population ages. Determining biomarkers for the early detection of underlying biology that will predict dementia progression reliably or, the monitoring of biological processes once present to track progression and treatment is necessary. Furthermore, these biomarkers will aid in the differentiation of dementia from normal ageing and between its subtypes, and in the development of sensitive and specific diagnostic and treatment methods. The current study will be the first to assess a new protein-aggregating biomarker of dementia, TAR-DNA-binding-protein-43 (TDP-43), in a population-based sample. TDP-43 was implicated in the biology of dementia in 2006 however its relevance to the population is unknown. This study will assess the significance of TDP-43 in relation to dementia in a population sample of older people who have undergone brain donation. The sample (n=350) is from the European Clinicopathological Studies in Europe (EClipSE). Each participant has been tracked longitudinally for up to twenty years (dependent on date of death), with clinical (e.g., dementia and other diagnoses such as diabetes, cognition and psychological symptomatology) data available. The three study objectives are: • The determination of the prevalence of pathological TDP-43 expression in a population-based sample of older people as a whole and relative to dementia status. • The determination of the relationships between pathological TDP-43 expression and other neuropathological markers of dementia as well as longitudinal cognition and psychological symptomatology. • The development of clinical criteria which are sensitive and specific to the presence of pathological TDP-43 expression during life. These investigations will have significant implications for the diagnosis, management and treatment of dementia syndromes, with the aim of decreasing the social and economic costs of dementia.'